Gaudium IVF and Women Health Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
GAUDIUMIVF · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.5 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gaudium IVF submitted its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, approved at a board meeting on March 18, 2026. On a consolidated basis, revenue from operations for Q3 FY26 stood at ₹2,450.70 lakhs, up about 70% from ₹1,442.48 lakhs in Q3 FY25, while nine-month revenue rose roughly 71% to ₹7,400.58 lakhs from ₹4,319.95 lakhs. Consolidated net profit for the nine months was ₹1,614.90 lakhs versus ₹1,260.26 lakhs last year (about 28% growth), though Q3 net profit grew only modestly to ₹363.08 lakhs. Standalone results were weaker, with Q3 net profit falling to ₹184.40 lakhs from ₹334.52 lakhs a year ago, even though nine-month standalone profit rose about 17% to ₹1,455.64 lakhs. The statutory auditor SKG N & Associates LLP issued an unmodified (clean) limited review report. The filing also notes the company recently completed its IPO on February 27, 2026, with shares listed on NSE and BSE, making this its first quarterly disclosure as a listed company.
For shareholders, the first post-listing results show strong top-line growth at the consolidated level driven by subsidiary expansion, supporting the growth narrative used at the IPO time. However, the sharp drop in standalone Q3 profit and rising finance/depreciation costs warrant a closer look at standalone profitability and margins before drawing strong conclusions.